NDAOTICSUSPENSION/DROPS
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIPRO HC (ciprofloxacin hydrochloride and hydrocortisone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1998.
Drug data last refreshed 5h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO HC is a fixed-dose combination otic suspension containing ciprofloxacin (fluoroquinolone antibiotic) and hydrocortisone (corticosteroid) approved in 1998 for treating ear infections. It combines anti-infective and anti-inflammatory action through the fluoroquinolone's bacterial activity and the corticosteroid's receptor agonism. The product is administered as ear drops for localized otic treatment.
$0.040BPart D
LOE ApproachingDeclining
As a legacy product in late lifecycle with modest Medicare utilization, this brand supports a lean team focused on lifecycle management and generic transition planning rather than growth initiatives.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Positions on the CIPRO HC team focus on lifecycle management, formulary retention, and transition planning in a declining market rather than growth or innovation. Career development potential is modest given the LOE timeline, but offers valuable experience in mature product stewardship and competitive defense within specialty pharmaceuticals.
Brand Manager
Worked on CIPRO HC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.